logo
Sign in

KNTPF Stock Price, Chart, Stats & News

Kintor Pharmaceutical Limited
Save

Kintor Pharmaceutical Limited (KNTPF) does not currently pay a dividend.

112.49M
Market cap
Current P/E
8.86x
Forward P/E

KNTPF chart

1M
3M
1Y
5Y
Loading chart...

About

Health care
Sector
Biotechnology
Industry

Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm dedicated to the development and commercialization of a diverse pipeline of small molecule and biologic treatments. Its primary focus is on addressing androgen-receptor-related conditions where current medical options are lacking, serving patients both within the People's Republic of China and globally. The company's innovative pipeline features several key candidates, such as Proxalutamide, a next-generation androgen receptor (AR) antagonist currently being investigated for metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19.

Similar securities

Based on sector and market capitalization

Report issue